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RESULTS
• Prior to the CLOT trial in 2003, Warfarin was first line 
therapy in  ≈90%  of cases
• Following 2003, there was a slow, steady decline in 
Warfarin corresponding with an increased use in LMWH
• DOACs became commercially available in the United 
States in 2010 and have seen exponential growth  since 
2014, accounting for 20% of cases in 2017
Non-Cognitive Predictors of Student Success:
A Predictive Validity Comparison Between Domestic and International Students
INTRODUCTION
• Transcatheter aortic valve replacement 
(TAVR) has evolved as the preferred 
treatment option for patients with severe 
aortic stenosis deemed at intermediate or 
higher risk for surgical aortic valve 
replacement (SAVR). 
• Although risk for SAVR is predominately 
determined by the Society for Thoracic 
Surgery (STS) predicted risk of mortality 
(PROM), Federal regulations permit local 
heart team latitude in offering TAVR  to 
patients with ≤3% PROM if risk for SAVR is 
not accurately reflected by the STS risk 
calculator.
• We aimed to identify the clinical factors 
that influenced the local heart teams to 
recommend TAVR in patients with ≤3% 
PROM and to compare their clinical 
characteristics and outcomes to TAVR 
patients with >3% PROM
METHODS
• Patients (n=2,539) who underwent TAVR 
from 2013-2017 were retrospectively 
identified within 8 hospitals in 5 Western 
States in the Providence St. Joseph Health 
system. 
• Clinical data was collected as per the STS 
ACC TVT Registry.
• Local TAVR coordinators completed surveys 
identifying the specific clinical factors that 
led the heart team to advise TAVR in 
patients with >3% PROM.
RESULTS
• 332 TAVR patients with >3% PROM
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Clinical Factors Leading to TAVR in Patients 
with < 3% PROM
Frailty, hostile chest, and severe lung disease were the 
most common reasons to recommend TAVR in 
patients with < 3.0% PROM
Patient Characteristics
≤3% STS PROM 
(n= 332 ) 
>3% STS PROM 
(n= 2207) 
Mean Age, years  sd 73.9  8.6 82  8.4
Male 69.6% 51.2%
STS PROM (%)  sd 2.3  0.5 7.1  3.8
Clinical outcomes
≤3% STS PROM 
(n= 332 ) 
>3% STS PROM 
(n= 2207) 
pLOS mean days  sd 2.5  3.7 3.2  3.6
In-hospital mortality 0.9% 2.4%
One year mortality % 
(95% CI)
7.5 (5.0, 11.2) 12.5 (11.1, 14.0)
CONCLUSION
• Over the study period, the proportion of TAVR 
patients with STS PROM ≤3% tripled. 
• The most common reason driving the decision for 
TAVR over SAVR in the ≤3% PROM group was frailty, 
hostile chest, and severe lung disease
• ≤3% PROM TAVR patients had shorter hospital stays 
and were more likely to be alive at 1 year 
